TrueMark Investments LLC Increases Stock Position in Johnson & Johnson $JNJ

TrueMark Investments LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 7.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,573 shares of the company’s stock after buying an additional 2,982 shares during the quarter. Johnson & Johnson makes up about 1.6% of TrueMark Investments LLC’s holdings, making the stock its 19th biggest holding. TrueMark Investments LLC’s holdings in Johnson & Johnson were worth $8,604,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Abich Financial Wealth Management LLC purchased a new stake in Johnson & Johnson in the third quarter worth about $26,000. Evolution Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $27,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $28,000. Semmax Financial Advisors Inc. increased its position in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares in the last quarter. Finally, Turning Point Benefit Group Inc. purchased a new position in Johnson & Johnson during the third quarter valued at $41,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.8%

Shares of NYSE:JNJ opened at $244.48 on Wednesday. The stock’s 50-day simple moving average is $238.40 and its two-hundred day simple moving average is $211.86. The stock has a market capitalization of $588.86 billion, a price-to-earnings ratio of 22.12, a PEG ratio of 2.40 and a beta of 0.34. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on JNJ shares. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. Stifel Nicolaus upped their price target on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Morgan Stanley set a $253.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, March 18th. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Finally, Sanford C. Bernstein increased their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $236.91.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royal Bank of Canada reaffirmed an “Outperform” rating and set a $255 price target on JNJ, implying roughly a mid-single-digit upside vs. the open — a clear analyst catalyst. RBC Reaffirms Outperform
• Positive Sentiment: Royalty Pharma agreed to co‑fund R&D with J&J ($500M) to advance JNJ‑4804, de‑risking and accelerating J&J’s immunology franchise and potential future revenue streams. Royalty Pharma Partnership
• Positive Sentiment: FDA approval of ICOTYDE and strong 52‑week ICONIC program durability data reinforce J&J’s immunology narrative and near‑term product commercialization upside. ICOTYDE Approval & Results
• Positive Sentiment: Multiple analyst/industry pieces reiterate J&J’s defensive, dividend‑king status and pipeline strength, which supports demand from income and risk‑averse investors amid volatility. Dividend/Defensive Coverage
• Positive Sentiment: Quant and value‑oriented writeups argue JNJ may still be attractively valued after the rally, providing buy‑the‑dip rationale for longer‑term investors. Quant Valuation Take
• Neutral Sentiment: Broader market strength — futures rallied after reports the U.S. may wind down direct military exposure in the Iran region — is a general tailwind that helped health care names including JNJ. Market/Macro News
• Negative Sentiment: Commentary highlighting J&J’s prior “free fall” and ongoing legal exposures keeps a valuation overhang for some investors, tempering upside. Cramer / Lawsuit Coverage
• Negative Sentiment: Macro risk sentiment (extreme Fear & Greed readings) remains elevated and could pressure cyclicals; defensive names can hold up but broader market drops would likely weigh on JNJ. Market Fear Index

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.